title: Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
abstract: We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1. He was diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy. We selected combined chemotherapy with both paclitaxel and S-1. Paclitaxel at 60 mg/m(2) was administered intraperitoneally on days 1 and 8, and S-1 at 100 mg/body was administered orally for 14 days, followed by 7 days' rest, as one course. After five courses, primary tumor reduction was confirmed and no cancer cells were detected on pathocytological investigation at second-look laparoscopy. The patient underwent total gastrectomy with lymph node dissection. He died from liver metastasis 29 months after the initial treatment, but he had not suffered from peritoneal metastases and had kept a good quality of life (QOL) since that treatment. This chemotherapy can be applied as one of the promising candidates for the treatment of patients with peritoneal metastasis of gastric cancer.
authors: Department of Surgery, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki, 660-8511, Japan.
authors: Shigeyuki
authors: S
authors: Tamura
authors: Hirofumi
authors: H
authors: Miki
authors: Ken
authors: K
authors: Nakata
authors: Daisuke
authors: D
authors: Takiuchi
authors: Kaoru
authors: K
authors: Okada
authors: Shin
authors: S
authors: Nakahira
authors: Shu
authors: S
authors: Okamura
authors: Keishi
authors: K
authors: Sugimoto
authors: Naohiro
authors: N
authors: Tomita
authors: Yuichi
authors: Y
authors: Takatsuka
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000284:Administration, Oral; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D006869:Hydronephrosis / Q000150:complications; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage*; D017239:Paclitaxel / Q000008:administration & dosage*; D010534:Peritoneal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D013274:Stomach Neoplasms / Q000150:complications / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel